Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells

Patients with castration-resistant prostate cancer (CRPC) can be treated with abiraterone, a potent inhibitor of androgen synthesis, or enzalutamide, a second-generation androgen receptor (AR) antagonist, both targeting AR signaling. However, most patients relapse after several months of therapy and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Assay Drug Dev Technol
Main Authors: Johnston, Paul A., Nguyen, Minh M., Dar, Javid A., Ai, Junkui, Wang, Yujuan, Masoodi, Khalid Z., Shun, Tongying, Shinde, Sunita, Camarco, Daniel P., Hua, Yun, Huryn, Donna M., Wilson, Gabriela Mustata, Lazo, John S., Nelson, Joel B., Wipf, Peter, Wang, Zhou
Formato: Artigo
Idioma:Inglês
Publicado: Mary Ann Liebert, Inc. 2016
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876501/
https://ncbi.nlm.nih.gov/pubmed/27187604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/adt.2016.716
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares